# Study of Docetaxel Combined with Cirmtuzumab in Metastatic Castration Resistant Prostate Cancer

> **NCT05156905** · PHASE1 · TERMINATED · sponsor: **University of California, San Diego** · enrollment: 6 (actual)

## Conditions studied

- Metastatic Castration-resistant Prostate Cancer

## Interventions

- **DRUG:** Cirmtuzumab

## Key facts

- **NCT ID:** NCT05156905
- **Lead sponsor:** University of California, San Diego
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-06-16
- **Primary completion:** 2024-10-01
- **Final completion:** 2024-10-01
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** Oncternal closing clinical trial operations.
- **Last updated:** 2024-10-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05156905

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05156905, "Study of Docetaxel Combined with Cirmtuzumab in Metastatic Castration Resistant Prostate Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05156905. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*